Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 29-35 , January 2008

Gadolinium-Containing MRI Contrast Agents: Important Variations on a Theme for NSF

  • Phillip H. Kuo, MD, PhD

      Affiliations

    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut.
    • Corresponding Author InformationCorresponding author and reprints: Phillip H. Kuo MD, PhD, Yale University School of Medicine, Department of Diagnostic Radiology, 333 Cedar Street, PO Box 20842, New Haven, CT 06520-8042.

References 

  1. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563–576
  2. Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B. Gd-DOTA (Pharmacokinetics and tolerability after intravenous injection into healthy volunteers). Invest Radiol. 1990;25:933–937
  3. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502
  4. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  5. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. [erratum] Nephrol Dial Transplant. 2006;21:1745
  6. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60:314–323
  7. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993;28(suppl):S28–S43
  8. Lorusso V, Pascolo L, Fernetti C, Anelli PL, Uggeri F, Tiribelli C. Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Des. 2005;11:4079–4098
  9. Biagi BA, Enyeart JJ. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. Am J Physiol. 1990;259:C515–C520
  10. Evans CH. Biochemistry of the lanthanides. New York: Plenum; 1990;
  11. Lansman JB. Blockade of current through single calcium channels by trivalent lanthanide cations (Effect of ionic radius on the rates of ion entry and exit). J Gen Physiol. 1990;95:679–696
  12. Quarles LD, Hartle JE, Middleton JP, Zhang J, Arthur JM, Raymond JR. Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem. 1994;56:106–117
  13. Tweedle MF. The ProHance story: the making of a novel MRI contrast agent. Eur Radiol. 1997;(suppl):225–230
  14. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467–481
  15. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41:272–278
  16. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128–137
  17. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649

PII: S1546-1440(07)00449-8

doi: 10.1016/j.jacr.2007.08.014

Journal of the American College of Radiology
Volume 5, Issue 1 , Pages 29-35 , January 2008

Article Tools

* Image Usage & Resolution